Three Or More Ring Hetero Atoms In The Tricyclo Ring System Patents (Class 546/82)
At least one of the ring hetero atoms is chalcogen (Class 546/83)
  • 1H-imidazo dimers
    Patent number: 6818650
    Abstract: 1H-imidazo dimer compounds are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: November 16, 2004
    Assignee: 3M Innovative Properties Company
    Inventor: George W. Griesgraber
  • Polysubstituted imidazopyridines
    Publication number: 20040214852
    Abstract: The invention relates to imidazopyridines of a certain formula 1, in which the substituents and symbols have the meanings indicated in the description. The compounds have gastric secretion-inhibiting properties.
    Type: Application
    Filed: May 24, 2004
    Publication date: October 28, 2004
    Applicant: Altana Pharma AG
    Inventors: Jorg Senn-Bilfinger, Wilm Buhr, Peter Zimmermann, Bernhard Kohl
  • Tricyclic heteroaromatic compounds
    Publication number: 20040214833
    Abstract: The invention relates to tricyclic heteroaromatic compounds of general formula (I) and the salts thereof 1
    Type: Application
    Filed: March 22, 2004
    Publication date: October 28, 2004
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Norbert Hauel, Henning Draheim
  • Sulfonamide substituted imidazoquinolines
    Publication number: 20040204438
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: April 16, 2004
    Publication date: October 14, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, Bryon A. Merrill
  • Tricyclic dihydroquinoline derivatives,method for preparing same and pharmaceutical compositions containing same
    Publication number: 20040198981
    Abstract: Compound of formula (I): 1
    Type: Application
    Filed: November 10, 2003
    Publication date: October 7, 2004
    Inventors: Henri-Philippe Husson, Sylviane Giorgi-Renault, Stephanie Desbene, John Hickman, Alain Pierre, Laurence Kraus-Berthier, Bruno Pfeiffer, Pierre Renard
  • Substituted 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives useful as phosphodiesterase inhibitors
    Patent number: 6800625
    Abstract: The invention relates to novel 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives of the formula (I) and (IV): wherein all variables are as herein defined, pharmaceutical compositions containing the compounds and their use for the treatment of sexual dysfunction.
    Type: Grant
    Filed: June 17, 2003
    Date of Patent: October 5, 2004
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Weiqin Jiang, Zhihua Sui
  • Sulfonamide and sulfamide substituted imidazoquinolines
    Patent number: 6800624
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: October 5, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
  • Imidazonaphthyridines
    Patent number: 6797716
    Abstract: Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: September 28, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Stephen L. Crooks, Philip D. Heppner, Gregory J. Marszalek, Peter V. Maye, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Novel tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing the same
    Publication number: 20040180917
    Abstract: A compound of formula (I): 1
    Type: Application
    Filed: November 10, 2003
    Publication date: September 16, 2004
    Inventors: Henri-Philippe Husson, Sylviane Giorgio-Renault, Stephanie Desbene, John Hickman, Alain Pierre, Laurence Kraus-Berthier, Bruno Pfeiffer, Pierre Renard
  • Glucocorticoid receptor modulators
    Publication number: 20040176595
    Abstract: The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonist and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediates and processes for preparing these compounds.
    Type: Application
    Filed: November 25, 2003
    Publication date: September 9, 2004
    Applicant: Pfizer, Inc.
    Inventors: Robert L. Dow, Kevin K. Liu, Bradley P. Morgan, Andrew G. Swick
  • 1-Amino 1H-imidazoquinolines
    Publication number: 20040176367
    Abstract: 1-Amino 1H-imidazoquinoline compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
    Type: Application
    Filed: March 5, 2004
    Publication date: September 9, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: George W. Griesgraber, Karl J. Manske
  • Methods and compounds for inhibitting MRP1
    Publication number: 20040176405
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Application
    Filed: March 10, 2004
    Publication date: September 9, 2004
    Inventors: Julian Kroin, Bryan Hurst Norman, Jeremy Schulenburg York
  • Urea substituted imidazoquinolines
    Patent number: 6784188
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: August 31, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
  • Pre-organized tricyclic integrase inhibitor compounds
    Publication number: 20040167124
    Abstract: Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.
    Type: Application
    Filed: October 16, 2003
    Publication date: August 26, 2004
    Applicant: GILEAD SCIENCES, INC.
    Inventors: James M. Chen, Xiaowu Chen, Maria Fardis, Haolun Jin, Choung U. Kim, Laura N. Schacherer
  • Urea substituted imidazoquinolines
    Publication number: 20040167154
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: February 17, 2004
    Publication date: August 26, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, Michael J. Rice
  • Urea substituted imidazoquinolines
    Patent number: 6780873
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: August 24, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, Bryon A. Merrill, Michael J. Rice
  • Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
    Patent number: 6780872
    Abstract: Compounds of formula I are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: August 24, 2004
    Assignee: Abbott Laboratories
    Inventors: Irene Drizin, Robert J. Altenbach, William A. Carroll
  • Tetrahydropyridoethers
    Publication number: 20040162310
    Abstract: Compounds of formula (1) in which the substituents have the meanings mentioned in the description, are suitable for the prevention and treatment of gastrointestinal diseases.
    Type: Application
    Filed: February 23, 2004
    Publication date: August 19, 2004
    Applicant: Altana Pharma AG.
    Inventor: Jorg Senn-Bilfinger
  • Amido ether substituted imidazoquinolines
    Publication number: 20040157874
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: October 7, 2003
    Publication date: August 12, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
  • Pre-organized tricyclic integrase inhibitor compounds
    Publication number: 20040157804
    Abstract: Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.
    Type: Application
    Filed: October 15, 2003
    Publication date: August 12, 2004
    Applicant: GILEAD SCIENCES, INC.
    Inventors: James M. Chen, Xiaowu Chen, Maria Fardis, Haolun Jin, Choung U. Kim, Laura N. Schacherer
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Patent number: 6770639
    Abstract: Disclosed are novel compounds of formula (I): wherein Ar1, Ra, R4, R5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases associated with such kinases, for example, diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are processes for preparing these compounds, novel intermediates useful in these processes and compositions comprising compounds of the formula (I).
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: August 3, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Roger John Snow, Mario Cardozo, Daniel Goldberg, Abdelhakim Hammach, Tina Morwick, Neil Moss, Usha R. Patel, Anthony S. Prokopowicz, III, Hidenori Takahashi, Matt Aaron Tschantz, Xiao-Jun Wang
  • Aryl substituted imidazoquinolines
    Publication number: 20040147543
    Abstract: Aryl substituted imidazoquinoline compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.
    Type: Application
    Filed: December 18, 2003
    Publication date: July 29, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: David S. Hays, Shri Niwas, Tushar Kshirsagar, Tarun K. Ghosh, Shalley K. Gupta, Phillip D. Heppner, Bryon A. Merrill, Jason D. Bonk, Michael E. Danielson, John F. Gerster, Chad A. Haraldson, Sarah Johannessen, Maureen A. Kavanagh, Kyle J. Lindstrom, Ryan B. Prince, Matthew R. Radmer, Michael J. Rice, David J. Squire, Sarah A. Strong, Joshua R. Wurst
  • Kinase inhibitors and associated pharmaceutical compositions and methods of use
    Publication number: 20040142916
    Abstract: The invention provides novel compounds useful as kinase inhibitors or as starting materials And/or intermediates in the synthesis of compounds useful as kinase inhibitors.
    Type: Application
    Filed: January 9, 2004
    Publication date: July 22, 2004
    Inventors: Paul A. Wender, Marc A. Scanio
  • 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives useful as antagonists of gonadotropin releasing hormone
    Patent number: 6765011
    Abstract: The present invention is directed to novel 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives of the general formula (I) or (II) wherein all variables are as herein defined, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions associated with gonadotropin releasing hormone (GnRH). The compounds of the invention are antagonists of GnRH, useful in the treatment of the infertility, prostate cancer, benign prostate hyperplasia (BPH) and as contraceptives.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: July 20, 2004
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Zhihua Sui, Mark Macielag, James C. Lanter
  • Aryl ether substituted imidazoquinolines
    Publication number: 20040138248
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: October 29, 2003
    Publication date: July 15, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Philip D. Heppner, Leslie J. Charles, Joseph F. Dellaria, Bryon A. Merrill, John W. Mickelson
  • Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
    Publication number: 20040138459
    Abstract: The invention provides 1H-imidazo(4,5-C)quinolin-4-phthalimide intermediates useful in the synthesis of 1H-imidazo(4,5-C)quinoline-4-amines, particularly Imiquimod. The invention further provides a method for making the intermediates and a method for making 1H-imidazo(4,5-C)quinoline-4-amines via the intermediates.
    Type: Application
    Filed: July 23, 2003
    Publication date: July 15, 2004
    Inventors: Valeriano Merli, Silvia Mantovani, Bianchi Stefano
  • Sulfonamide and sulfamide substituted imidazoquinolines
    Publication number: 20040132762
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: December 12, 2003
    Publication date: July 8, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
  • Amide substituted imidazoquinolines
    Patent number: 6756382
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: June 29, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: Patrick L. Coleman, Stephen L. Crooks, George W. Griesgraber, Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
  • Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
    Publication number: 20040122231
    Abstract: A method of preparing intermediates for making 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines is disclosed.
    Type: Application
    Filed: December 9, 2003
    Publication date: June 24, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: John F. Gerster, Stephen L. Crooks, Kyle J. Lindstrom
  • Isoxazoline derivatives as anti-depressants
    Publication number: 20040122037
    Abstract: The invention concerns substituted isoxazolines derivatives according to Formula (I): wherein X=CH?2#191, N—R7, S or O, R1, R2 and R3 are certain specific substituents, Pir is an optionally substituted piperidyl or piperazyl radical and R3 represents an optionally substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Pir radical and which may contain one or more heteroatoms selected from the group of O, N and S ; a process for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for the treatment of depression and/of anxiety and disorders of body weight.
    Type: Application
    Filed: August 21, 2003
    Publication date: June 24, 2004
    Inventors: Jose Ignacio Andres-Gil, Francisco Javier Fernandez-Gadea, Manuel Jesus Alcazar-Vaca, Jose Maria Cid-Nunez, Joaquin Pastor-Fernandez, Antonius Adrianus Henrikus Petrus Megens, Godelieve Maria Heylen, Xavier Jean Michel Langlois, Margaretha Henrica Maria Bakker, Thomas Horst Wolfgang Steckler
  • Immunomodulatory compounds
    Publication number: 20040116461
    Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.
    Type: Application
    Filed: November 21, 2003
    Publication date: June 17, 2004
    Applicant: ACTIVE BIOTECH AB
    Inventors: Ian Richard Matthews, Thomas Stephen Coulter, Chiara Ghiron, Chris James Brennan, Muhammed Kamal Uddin, Lars Olof Goran Pettersson, Dorthe da Graca Thrige, Philip Huxley
  • Substituted beta carbolines
    Publication number: 20040110759
    Abstract: The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, 1
    Type: Application
    Filed: July 28, 2003
    Publication date: June 10, 2004
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne W. Hancock, Hormoz Mazdiyasni, Vito Palombella, Julian Adams
  • Imidazonaphthyridines
    Patent number: 6747040
    Abstract: Imidazonaphthyridine compounds that are unsubstituted at the 2-position induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
    Type: Grant
    Filed: April 2, 2003
    Date of Patent: June 8, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: Kyle J. Lindstrom, Michael J. Rice
  • Aryl ether substituted imidazoquinolines
    Publication number: 20040106640
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: October 29, 2003
    Publication date: June 3, 2004
    Inventors: Leslie J. Charles, Joseph F. Dellaria, Philip D. Heppner, Bryon A. Merrill, John W. Mickelson
  • Methods and compounds for inhibiting MRP1
    Patent number: 6743794
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: June 1, 2004
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst, Qiupang Wang
  • Sulfonamido ether substituted imidazoquinolines
    Publication number: 20040097542
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and sulfonamide or sulfamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: October 29, 2003
    Publication date: May 20, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill, Ralph R. Roberts, Ai-Ping Wei
  • Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase
    Publication number: 20040097541
    Abstract: Compounds of the formula I 1
    Type: Application
    Filed: July 3, 2003
    Publication date: May 20, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Stefanie Flohr, Thorsten Naumann
  • Thioether substituted imidazoquinolines
    Publication number: 20040097736
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: October 29, 2003
    Publication date: May 20, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Jason D. Bonk, Joseph F. Dellaria, Bryon A. Merrill, Matthew R. Radmer
  • Sulfonamido ether substituted imidazoquinolines
    Publication number: 20040092545
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and sulfonamide or sulfamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: October 29, 2003
    Publication date: May 13, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill, Ralph R. Roberts, Ai-Ping Wei
  • Dihydrodipyrazolopyridinylbenzamide and -sulfonamide inhibitors of B7-1
    Patent number: 6734190
    Abstract: The present invention provides a compound of formula I and the use thereof for the immunotherapeutic treatment of transplant rejection or autoimmune disease.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: May 11, 2004
    Assignee: Wyeth
    Inventors: Neal Jeffrey Green, Jason Shaoyun Xiang, Audrey Molina Davies, Lihren Chen
  • Urea substituted imidazoquinoline ethers
    Publication number: 20040077678
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: October 7, 2003
    Publication date: April 22, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
  • Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient
    Publication number: 20040072833
    Abstract: Tri-heterocyclic compound of formula (I) 1
    Type: Application
    Filed: June 30, 2003
    Publication date: April 15, 2004
    Inventors: Hisao Nakai, Yoshifumi Kagashimi
  • Heterocyclic ether substituted imidazoquinolines
    Publication number: 20040072858
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and heterocyclyl or heteroaryl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: September 30, 2003
    Publication date: April 15, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Leslie J. Charles, Joseph F. Dellaria, George W. Griesgraber, Philip D. Heppner, Karl J. Manske, John W. Mickelson, Michael J. Rice
  • Pest controllers
    Publication number: 20040067852
    Abstract: An objective of the present invention is to provide a harmful organism control agent that possesses excellent control effect against harmful organisms and can be safely used. The present invention provides a compound of formula (1) or a salt thereof. The present invention also provides a harmful organism control agent comprising the compound of formula (1).
    Type: Application
    Filed: July 31, 2003
    Publication date: April 8, 2004
    Inventors: Kazuhiko Oyama, Takeshi Teraoka, Kazumi Yamamoto
  • Amido ether substituted imidazoquinolines
    Publication number: 20040067975
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: October 7, 2003
    Publication date: April 8, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
  • Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates
    Publication number: 20040063743
    Abstract: The invention relates to a process for the synthesis of 1H-imidazo[4,5-c] quinoline 4-cyano and 1H-imidazo[4,5-c] quinoline 4-carboxamide intermediates useful in preparing 1H-imidazo[4,5-C] quinoline 4-amines, a process for preparing 1H-imidazo[4,5-C] quinoline 4-amines using such intermediates; and, to the 1H-imidazo[4,5-c] quinoline 4-cyano and 1H-imidazo[4,5-c] quinoline 4-carboxamide intermediates. More particularly, the invention relates to a process for the preparation of 1-isobutyl-1H-imidazo[4,5-C] quinoline 4-amine (Imiquimod) using two intermediates, 1-isobutyl-1H-imidazo[4,5-c] quinoline 4-cyano and 1-isobutyl-1H-imidazo[4,5-c] quinoline 4-carboxamide, and to the said intermediates.
    Type: Application
    Filed: July 28, 2003
    Publication date: April 1, 2004
    Inventors: Valeriano Merli, Silvia Mantovani, Bianchi Stefano
  • 1h-imidazopyridine derivatives
    Publication number: 20040054182
    Abstract: A 1H-imidazopyridine derivative represented by the following general formula (I) or a salt thereof having an inhibitory action against production of a cytokine: 1
    Type: Application
    Filed: August 23, 2002
    Publication date: March 18, 2004
    Inventors: Hideo Kato, Jun Sakaguchi, Tomoyuki Izumi, Ken-ichi Kato
  • Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
    Patent number: 6703402
    Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: March 9, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Compounds, their preparation and use
    Patent number: 6703401
    Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by clear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: March 9, 2004
    Assignees: Novo Nordisk A/S, Dr. Reddy's Research Foundation
    Inventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
  • Dihydrodipyrazolopyridinone inhibitors of B7-1
    Publication number: 20040044024
    Abstract: The present invention provides a compound of formula I and the use thereof for the immunotherapeutic treatment of transplant rejection, autoimmune disease or graft vs. host disease.
    Type: Application
    Filed: July 28, 2003
    Publication date: March 4, 2004
    Applicant: Wyeth
    Inventors: Neal Jeffrey Green, Steve Yikkai Tam, Jason Shaoyun Xiang, Audrey Molina Davies, Lihren Chen, Gary Paul Stack